Masimo Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Masimo de 28.9% y 4.7% respectivamente, mientras que el BPA crecerá en un 27% al año.

Información clave

28.9%

Tasa de crecimiento de los beneficios

27.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.1%
Tasa de crecimiento de los ingresos	4.7%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	25 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Masimo Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 29

Recent updates

Is There Now An Opportunity In Masimo Corporation (NASDAQ:MASI)?

Apr 13

Masimo Corporation's (NASDAQ:MASI) Popularity With Investors Is Under Threat From Overpricing

Mar 28

Masimo Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 29

Estimating The Intrinsic Value Of Masimo Corporation (NASDAQ:MASI)

Feb 24

Masimo: Given The Lack Of Improvement In Revenues And Margins, It Is A Little Expensive

Feb 18

These 4 Measures Indicate That Masimo (NASDAQ:MASI) Is Using Debt Extensively

Feb 08

Earnings Tell The Story For Masimo Corporation (NASDAQ:MASI) As Its Stock Soars 27%

Dec 23

At US$112, Is It Time To Put Masimo Corporation (NASDAQ:MASI) On Your Watch List?

Dec 14

Masimo Corporation (NASDAQ:MASI) Shares Could Be 38% Below Their Intrinsic Value Estimate

Nov 09

Is Masimo Corporation (NASDAQ:MASI) Expensive For A Reason? A Look At Its Intrinsic Value

Nov 02

Should You Think About Buying Masimo Corporation (NASDAQ:MASI) Now?

Sep 16

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:MASI - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	2,368	196	394	484	9
12/31/2025	2,228	163	347	434	10
12/31/2024	2,102	109	176	226	10
12/30/2023	2,048	82	6	94	N/A
9/30/2023	2,116	89	-58	10	N/A
7/1/2023	2,187	116	-28	28	N/A
4/1/2023	2,297	118	-45	7	N/A
12/31/2022	2,036	144	-27	29	N/A
10/1/2022	1,746	171	78	134	N/A
7/2/2022	1,505	191	147	205	N/A
4/2/2022	1,244	223	181	229	N/A
1/1/2022	1,239	230	230	265	N/A
10/2/2021	1,207	232	188	232	N/A
7/3/2021	1,177	224	149	190	N/A
4/3/2021	1,173	229	176	228	N/A
1/2/2021	1,144	240	131	211	N/A
9/26/2020	1,096	223	138	217	N/A
6/27/2020	1,047	222	148	227	N/A
3/28/2020	976	211	119	222	N/A
12/28/2019	938	196	149	222	N/A
9/28/2019	913	190	150	215	N/A
6/29/2019	895	198	153	212	N/A
3/30/2019	877	197	187	210	N/A
12/29/2018	858	194	217	240	N/A
9/29/2018	843	139	201	225	N/A
6/30/2018	826	118	149	199	N/A
3/31/2018	807	119	65	114	N/A
12/30/2017	790	125	9	56	N/A
9/30/2017	766	348	N/A	338	N/A
7/1/2017	740	340	N/A	347	N/A
4/1/2017	720	325	N/A	414	N/A
12/31/2016	713	311	N/A	419	N/A
10/1/2016	672	109	N/A	150	N/A
7/2/2016	657	101	N/A	145	N/A
4/2/2016	640	90	N/A	117	N/A
1/2/2016	623	83	N/A	117	N/A
10/3/2015	623	80	N/A	85	N/A
7/4/2015	613	76	N/A	86	N/A
4/4/2015	596	70	N/A	91	N/A
1/3/2015	580	73	N/A	96	N/A
9/27/2014	556	61	N/A	73	N/A
6/28/2014	545	61	N/A	61	N/A
3/29/2014	543	65	N/A	54	N/A
12/28/2013	541	58	N/A	55	N/A
9/28/2013	537	64	N/A	67	N/A
6/29/2013	525	62	N/A	77	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (28.9% al año) de MASI es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que los beneficios (28.9% al año) de MASI crezcan más rápidamente que el mercado US (14.7% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de MASI crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (4.7% al año) de MASI crezcan más despacio que el mercado de US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 4.7% al año) de MASI crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de MASI se prevé que sea elevada dentro de 3 años.

Masimo Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 12% to US$135

Masimo Corporation Reaffirms Financial Guidance for the First Quarter and Fiscal Year 2024

Masimo Corporation Provides Consolidated Earnings Guidance for the Fourth-Quarter and Full-Year 2024

Masimo Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Price target increased by 13% to US$128

Price target increased by 17% to US$108

Recent updates

Lead Independent Director notifies of intention to sell stock

Masimo Corporation to Report Q1, 2024 Results on May 07, 2024

Is There Now An Opportunity In Masimo Corporation (NASDAQ:MASI)?

Masimo Corporation's (NASDAQ:MASI) Popularity With Investors Is Under Threat From Overpricing

Price target increased by 12% to US$135

Masimo Corporation Reaffirms Financial Guidance for the First Quarter and Fiscal Year 2024

Masimo Corporation(NasdaqGS:MASI) dropped from FTSE All-World Index (USD)

Masimo Corporation Provides Consolidated Earnings Guidance for the Fourth-Quarter and Full-Year 2024

Masimo Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Full year 2023 earnings: EPS exceeds analyst expectations

Price target increased by 13% to US$128

Estimating The Intrinsic Value Of Masimo Corporation (NASDAQ:MASI)

Now 20% undervalued

Masimo: Given The Lack Of Improvement In Revenues And Margins, It Is A Little Expensive

Masimo Corporation Announces Board Changes

Masimo Announces the First FDA-Cleared “Over-The-Counter” Fingertip Pulse Oximeter

These 4 Measures Indicate That Masimo (NASDAQ:MASI) Is Using Debt Extensively

Masimo Corporation to Report Q4, 2023 Results on Feb 27, 2024

Masimo Announces Reinstatement of Import Ban on Infringing Apple Watches

Masimo Corporation Appoints Bob Chapek to the Board of Directors

Price target increased by 17% to US$108

Masimo Corporation Provides Consolidated Earnings Guidance for the Fourth Quarter and Full Year Ended December 30, 2023 and Full Year 2024

Earnings Tell The Story For Masimo Corporation (NASDAQ:MASI) As Its Stock Soars 27%

Masimo Receives FDA Clearance for Stork™ Baby Monitoring System

At US$112, Is It Time To Put Masimo Corporation (NASDAQ:MASI) On Your Watch List?

Masimo W1™ Medical Watch Receives FDA 510(K) Clearance for Over-The-Counter and Prescription Use

Consensus EPS estimates fall by 33%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Masimo Corporation (NASDAQ:MASI) Shares Could Be 38% Below Their Intrinsic Value Estimate

Price target decreased by 25% to US$96.14

Masimo Corporation Provides Earnings Guidance for the Fourth-Quarter and Full-Year 2023

Masimo Corporation to Report Q3, 2023 Results on Nov 07, 2023

Howard G. Smith Announces Securities Fraud Lawsuit Against Masimo Corporation

Masimo ORi™ Granted De Novo as the First and Only FDA-Cleared Noninvasive and Continuous Parameter to Provide Insight into Hyperoxia Under Supplemental Oxygen

Investor sentiment deteriorates as stock falls 16%

Is Masimo (NASDAQ:MASI) Using Too Much Debt?

Rosen Law Firm Announces the Filing of A Class Action Lawsuit on Behalf of Purchasers of Securities of Masimo Corporation

Consensus EPS estimates fall by 22%

Masimo Corporation Provides Earnings Guidance for the Third-Quarter and Full-Year 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is There Now An Opportunity In Masimo Corporation (NASDAQ:MASI)?

Consensus EPS estimates fall by 25%

Consensus EPS estimates fall by 16%

Investor sentiment deteriorates as stock falls 24%

Price target decreased by 18% to US$155

Masimo Corporation to Report Q2, 2023 Results on Aug 08, 2023

Masimo Corporation Approves Board Elections

Masimo Corporation(NasdaqGS:MASI) dropped from Russell Small Cap Comp Value Index

Masimo Expands into the Personalized Hearables Market with Denon Perl™? True Wireless Earbuds, Featuring Masimo Aat™?

Here's Why Masimo (NASDAQ:MASI) Has A Meaningful Debt Burden

Politan Capital Management Sends a Letter to Shareholders of Masimo Corporation

Masimo Corporation Appoints Michelle Brennan as Sixth Director

Founder recently bought US$1.0m worth of stock

Politan Capital Management LP Posts Presentation to the Website

Politan Capital Releases Investor Presentation to Shareholders of Masimo Corporation

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Masimo Corporation Provides Earnings Guidance for the Full Year of 2023

Is It Too Late To Consider Buying Masimo Corporation (NASDAQ:MASI)?

Politan Capital Launches a Website in Connection with the Solicitation of Stockholders

Politan Capital Management Nominates Candidates for Masimo Board

Masimo (NASDAQ:MASI) Seems To Use Debt Quite Sensibly

Full year 2022 earnings: EPS misses analyst expectations

Price target increased by 14% to US$188

Masimo Corporation to Report Q4, 2022 Results on Feb 28, 2023

When Should You Buy Masimo Corporation (NASDAQ:MASI)?

Masimo Corporation Announces the Limited Market Release of Visual Clinical Activity Monitoring (VCAM™)

Masimo Announces New Study Evaluates the Performance of Masimo Sphb Noninvasive Spot-Check Hemoglobin in the Emergency Department

Masimo Patient SafetyNet™ Helped Clinicians Reduce CPR Events and Rates, Improve CPR Success Rate, and Reduce Hospital Length of Stay and Mortality

Masimo Announces New Prospective Study Evaluates the Accuracy of Masimo SpHb® Noninvasive and Continuous Hemoglobin Monitoring During Elective Cesarean Section